Payment overview · 2025
General Payments
$470.60
24 reported records · 10 companies
Healthcare provider profile · identity verified
David Edgar Vann, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SHARPSBURG, GA · NPI 1760466742
Verified facts
What the public records show
CMS Open Payments records show David Edgar Vann, M.D. received $470.60 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $117.00 | 24.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.59 | 17.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.98 | 13.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.12 | 11.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.88 | 9.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.75 | 7.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.36 | 6.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.70 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.20 | 3.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.02 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $470.60 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.73 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.73 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.98 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $60.98 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $60.98 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.12 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.75 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 212 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 124 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
124 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1232 | 376 |
| Atorvastatin Calcium | Atorvastatin Calcium | 918 | 277 |
| Levothyroxine Sodium | Levothyroxine Sodium | 780 | 232 |
| Omeprazole | Omeprazole | 733 | 239 |
| Losartan Potassium | Losartan Potassium | 627 | 201 |
| Lisinopril | Lisinopril | 592 | 177 |
| Alprazolam | Alprazolam | 574 | 95 |
| Clonazepam | Clonazepam | 565 | 114 |
| Gabapentin | Gabapentin | 522 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 500 | 145 |
| Metformin Hcl | Metformin Hcl | 477 | 137 |
| Zolpidem Tartrate | Zolpidem Tartrate | 461 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 434 | 139 |
| Hydrochlorothiazide | Hydrochlorothiazide | 394 | 125 |
| Escitalopram Oxalate | Escitalopram Oxalate | 364 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 354 | 101 |
| Simvastatin | Simvastatin | 352 | 106 |
| Metoprolol Tartrate | Metoprolol Tartrate | 328 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 91 |
| Meloxicam | Meloxicam | 293 | 96 |
| Tramadol Hcl | Tramadol Hcl | 287 | 71 |
| Glimepiride | Glimepiride | 268 | 76 |
| Trazodone Hcl | Trazodone Hcl | 267 | 81 |
| Sertraline Hcl | Sertraline Hcl | 250 | 80 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 245 | 61 |
| Allopurinol | Allopurinol | 235 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 71 |
| Furosemide | Furosemide | 213 | 72 |
| Eliquis | Apixaban | 212 | 46 |
| Lorazepam | Lorazepam | 211 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 54 |
| Montelukast Sodium | Montelukast Sodium | 194 | 56 |
| Carvedilol | Carvedilol | 173 | 57 |
| Potassium Chloride | Potassium Chloride | 173 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 169 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 52 |
| Fenofibrate | Fenofibrate | 164 | 50 |
| Ozempic | Semaglutide | 161 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 160 | 50 |
| Celecoxib | Celecoxib | 156 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 42 |
| Jardiance | Empagliflozin | 140 | 39 |
| Donepezil Hcl | Donepezil Hcl | 139 | 45 |
| Metformin Hcl Er | Metformin Hcl | 138 | 38 |
| Atenolol | Atenolol | 136 | 36 |
| Ezetimibe | Ezetimibe | 135 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 29 |
| Mounjaro | Tirzepatide | 124 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 29 |
| Bupropion Xl | Bupropion Hcl | 106 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 21 |
| Temazepam | Temazepam | 104 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 103 | 87 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 33 |
| Sucralfate | Sucralfate | 96 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 32 |
| Azithromycin | Azithromycin | 84 | 75 |
| Synthroid | Levothyroxine Sodium | 83 | 23 |
| Januvia | Sitagliptin Phosphate | 80 | 16 |
| Methylprednisolone | Methylprednisolone | 79 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 24 |
| Glipizide | Glipizide | 74 | 23 |
| Valacyclovir | Valacyclovir Hcl | 74 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 20 |
| Famotidine | Famotidine | 68 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | suppressed |
| Valsartan | Valsartan | 64 | 20 |
| Diazepam | Diazepam | 63 | 18 |
| Prednisone | Prednisone | 63 | 25 |
| Memantine Hcl | Memantine Hcl | 62 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 21 |
| Cefdinir | Cefdinir | 61 | 53 |
| Meclizine Hcl | Meclizine Hcl | 60 | 33 |
| Pregabalin | Pregabalin | 60 | 20 |
| Alendronate Sodium | Alendronate Sodium | 59 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 53 |
| Clonidine Hcl | Clonidine Hcl | 56 | 16 |
| Ibuprofen | Ibuprofen | 54 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 16 |
| Methocarbamol | Methocarbamol | 53 | 25 |
| Telmisartan | Telmisartan | 53 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 50 | suppressed |
| Myrbetriq | Mirabegron | 50 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Azelastine Hcl | Azelastine Hcl | 47 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 38 |
| Fluconazole | Fluconazole | 47 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Warfarin Sodium | Warfarin Sodium | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 41 | 14 |
| Lovastatin | Lovastatin | 41 | 14 |
| Promethazine Hcl | Promethazine Hcl | 41 | 12 |
| Trulicity | Dulaglutide | 41 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Estradiol | Estradiol | 39 | 11 |
| Klor-Con M20 | Potassium Chloride | 39 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 14 |
| Baclofen | Baclofen | 37 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Finasteride | Finasteride | 35 | 14 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | 11 |
| Lansoprazole | Lansoprazole | 34 | 13 |
| Nystatin | Nystatin | 34 | 18 |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 15 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Mometasone Furoate | Mometasone Furoate | 28 | 24 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | 12 |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 11 |
| Testosterone | Testosterone | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Linzess | Linaclotide | 19 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Gemtesa | Vibegron | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $470.60 · 24 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, GEMTESA, Heplisav-B, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, SHINGRIX, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error